Lenalidomide Stada Arzneimittel Stada Arzneimittel Ag (Lenalidomide)

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders.

• Multiple myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease.
• Myelodysplastic syndromes: reduces transfusion dependence and delays transformation to acute leukemia in patients with del(5q) cytogenetic abnormality.
• Relapsed or refractory multiple myeloma: provides therapeutic benefit after failure of prior therapies, including proteasome inhibitors and immunomodulators.

• Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, altering substrate specificity and promoting degradation of transcription factors Ikaros and Aiolos. This leads to modulation of cytokine production, inhibition of angiogenesis, and activation of T‑ and NK‑cell mediated immune responses, ultimately inducing apoptosis of malignant plasma cells. Additionally, lenalidomide down‑regulates adhesion molecules, reducing tumor cell interaction with the bone marrow microenvironment.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Neutropenia: decreased neutrophil count increasing infection risk.
• Thrombocytopenia: lowered platelet levels leading to bleeding.
• Fatigue: persistent tiredness affecting daily activities.
• Nausea: mild to moderate gastrointestinal upset.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
• Severe infections: opportunistic or bacterial infections requiring hospitalization.
• Stevens‑Johnson syndrome: severe skin reaction with mucosal involvement.

When prescribing lenalidomide, several safety considerations are essential.

• Pregnancy: contraindicated; avoid use in pregnant women and ensure effective contraception.
• Thrombosis risk: assess patient history and consider prophylactic anticoagulation.
• Renal impairment: monitor renal function and adjust dosing as recommended.
• Hematologic monitoring: perform regular complete blood counts to detect cytopenias.
• Drug interactions: review concomitant medications for potential interactions.
• Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Lenalidomide can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Thalidomide: combined use markedly increases teratogenic risk.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): substantially reduce lenalidomide exposure.
• Anticoagulants (e.g., warfarin): may enhance anticoagulant effect and increase bleeding risk.

Moderate Interactions (Monitor Closely)

• P‑glycoprotein inhibitors (e.g., verapamil): may raise plasma concentrations of lenalidomide.
• Live vaccines: immunosuppression can lead to vaccine‑derived infection.